{"id":"best-available-therapy-bat","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL302424","moleculeType":"Small molecule","molecularWeight":"344.43"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"BAT (Best Available Therapy) is a trial design element representing the standard-of-care or most effective existing treatment for a given condition, used as a control arm to benchmark investigational drugs. It is not itself a pharmaceutical agent with a defined molecular mechanism.","oneSentence":"BAT is a best available therapy comparator arm used in clinical trials, not a drug with its own mechanism of action.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:04:02.196Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT05639647","phase":"PHASE2","title":"Study of 2 Medicines (Aztreonam and Avibactam) Compared to Best Available Therapy for Serious Gram-negative Infections","status":"RECRUITING","sponsor":"Pfizer","startDate":"2023-04-18","conditions":"Gram-negative Bacterial Infections","enrollment":48},{"nctId":"NCT06925321","phase":"PHASE3","title":"A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Patients With Invasive Mold Infections.","status":"RECRUITING","sponsor":"Basilea Pharmaceutica","startDate":"2025-08-26","conditions":"Invasive Mold Infections","enrollment":219},{"nctId":"NCT06821542","phase":"PHASE3","title":"A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Incyte Corporation","startDate":"2025-06-04","conditions":"Chronic Graft-versus-host-disease","enrollment":9},{"nctId":"NCT07124078","phase":"PHASE2","title":"A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)","status":"RECRUITING","sponsor":"Incyte Corporation","startDate":"2026-03-31","conditions":"Chronic Graft-versus-host-disease","enrollment":60},{"nctId":"NCT05905055","phase":"PHASE3","title":"P3 Study to Assess Efficacy and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam Versus Best Available Therapy for Adults With Infection Due to Carbapenem Resistant Enterobacterales","status":"COMPLETED","sponsor":"Meiji Seika Pharma Co., Ltd.","startDate":"2023-09-22","conditions":"Complicated Urinary Tract Infection, Acute Pyelonephritis, Hospital-acquired Bacterial Pneumonia","enrollment":126},{"nctId":"NCT06079879","phase":"PHASE3","title":"A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-12-31","conditions":"Essential Thrombocythemia","enrollment":340},{"nctId":"NCT07431307","phase":"PHASE2","title":"Safety, Pharmacokinetics and Efficacy of BV100 Plus Low Dose Polymyxin B Plus Ceftazidime/Avibactam, or Plus Cefiderocol in Patients With Pulmonary and Extrapulmonary Infections Due to Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex","status":"NOT_YET_RECRUITING","sponsor":"BioVersys AG","startDate":"2026-07","conditions":"Ventilator Associated Bacterial Pneumonia (VABP), Hospital Acquired Bacterial Pneumonia (HABP), Blood Stream Infection","enrollment":120},{"nctId":"NCT06075706","phase":"PHASE2","title":"Trial of Efficacy and Safety of MC0518 Versus Best Available Therapy in Participants With Steroid-Refractory Acute Graft Versus Host Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"medac GmbH","startDate":"2023-11-13","conditions":"Steroid-refractory Acute Graft-versus-host Disease","enrollment":48},{"nctId":"NCT04217356","phase":"","title":"Study of Stem Cell Transplant vs. Non-Transplant Therapies in High-Risk Myelofibrosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2020-08-05","conditions":"Myelofibrosis, High-Risk Cancer, Bone Marrow Cancer","enrollment":90},{"nctId":"NCT04468984","phase":"PHASE3","title":"Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2020-08-31","conditions":"Myelofibrosis (MF)","enrollment":330},{"nctId":"NCT04047628","phase":"PHASE3","title":"Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-12-19","conditions":"Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis","enrollment":156},{"nctId":"NCT06646016","phase":"PHASE2","title":"EPIC- Extracorporeal Photopheresis (ECP) for Immune-related Colitis","status":"WITHDRAWN","sponsor":"Therakos LLC","startDate":"2025-12-15","conditions":"Immune-related Colitis","enrollment":""},{"nctId":"NCT04576156","phase":"PHASE3","title":"A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Geron Corporation","startDate":"2021-04-12","conditions":"Myelofibrosis","enrollment":327},{"nctId":"NCT07226557","phase":"","title":"Cefiderocol vs Best Available Therapy for Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex Infections: A Target Trial Emulation","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institutes of Health Clinical Center (CC)","startDate":"2025-01-01","conditions":"Carbapenem Resistant Bacterial Infection, Acinetobacter Baumannii Infection, Antimicrobial Drug Resistance","enrollment":5000},{"nctId":"NCT03952039","phase":"PHASE3","title":"An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib","status":"COMPLETED","sponsor":"Celgene","startDate":"2019-09-09","conditions":"Primary Myelofibrosis, Post-Polycythemia Vera, Myelofibrosis","enrollment":202},{"nctId":"NCT04629833","phase":"PHASE3","title":"Treatment Of Steroid-Refractory Acute Graft-versus-host Disease With Mesenchymal Stromal Cells Versus Best Available Therapy","status":"RECRUITING","sponsor":"medac GmbH","startDate":"2021-08-16","conditions":"Steroid-refractory Acute Graft-versus-host Disease","enrollment":210},{"nctId":"NCT03112603","phase":"PHASE3","title":"A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2017-06-29","conditions":"Graft-versus-host Disease (GVHD)","enrollment":330},{"nctId":"NCT05132166","phase":"PHASE2","title":"A Randomized Phase II Study to Compare the Potential Long-Lasting Positive Effect of Decidual Stromal Cells to the Best Available Treatment in Graft Versus Host Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2021-12-22","conditions":"Graft Vs Host Disease","enrollment":50},{"nctId":"NCT02577926","phase":"PHASE2","title":"The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"RWTH Aachen University","startDate":"2015-10","conditions":"Polycythemia Vera (PV), Essential Thrombocythemia (ET)","enrollment":207},{"nctId":"NCT04854096","phase":"PHASE2","title":"Study to Assess Efficacy and Safety of NS-018 Compared to BAT in Patients With Myelofibrosis","status":"TERMINATED","sponsor":"NS Pharma, Inc.","startDate":"2023-01-31","conditions":"Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Post-polycythemia Vera Myelofibrosis","enrollment":7},{"nctId":"NCT04795427","phase":"PHASE2","title":"Study of Efficacy and Safety of CML-CP Patients Treated With Asciminib Versus Best Available Therapy, Previously Treated With 2 or More Tyrosine Kinase Inhibitors","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-12-06","conditions":"Leukemia, Chronic Myelogenous","enrollment":84},{"nctId":"NCT04126681","phase":"PHASE2","title":"A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase","status":"COMPLETED","sponsor":"Ascentage Pharma Group Inc.","startDate":"2019-10-21","conditions":"Chronic Myeloid Leukemia, Chronic Phase","enrollment":144},{"nctId":"NCT05685615","phase":"PHASE2","title":"PK of BV100 in Patients VABP Suspected or Confirmed to Be Due to CRAB","status":"COMPLETED","sponsor":"BioVersys AG","startDate":"2023-04-20","conditions":"Ventilator Associated Pneumonia","enrollment":39},{"nctId":"NCT04118556","phase":"PHASE2","title":"Decidua Stroma Cells for Steroid Resistent Acute Graft-versus-host Disease After Allo-HSCT","status":"RECRUITING","sponsor":"Mats Remberger","startDate":"2021-12-01","conditions":"GVHD, Acute","enrollment":50},{"nctId":"NCT04116502","phase":"PHASE3","title":"MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera","status":"RECRUITING","sponsor":"University of Birmingham","startDate":"2019-10-25","conditions":"Polycythemia Vera","enrollment":586},{"nctId":"NCT06677255","phase":"PHASE1, PHASE2","title":"A Phase I/II Trial of VUM02 Injection for Steroid-refractory Acute Graft-versus-host Disease (SR-aGvHD) Treatment","status":"NOT_YET_RECRUITING","sponsor":"Wuhan Optics Valley Vcanbiopharma Co., Ltd.","startDate":"2025-01","conditions":"Steroid-refractory Acute Graft-versus-host Disease","enrollment":149},{"nctId":"NCT04882085","phase":"PHASE4","title":"Efficacy and Safety of CAZ-AVI in the Treatment of Infections Due to Carbapenem-resistant G- Pathogens in Chinese Adults","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-08-26","conditions":"Urinary Tract Infection, Acute Pyelonephritis, Hospital Acquired Pneumonia","enrollment":60},{"nctId":"NCT04900337","phase":"PHASE1, PHASE2","title":"Safety, Tolerability and Efficacy of Amorphous Calcium Carbonate (ACC) Compared to Placebo and Best Available Care (BAT), for the Treatment of Moderate to Severe COVID-19 Patients.","status":"COMPLETED","sponsor":"Amorphical Ltd.","startDate":"2021-02-09","conditions":"Covid19","enrollment":66},{"nctId":"NCT03869437","phase":"PHASE2","title":"RCT Cefiderocol vs BAT for Treatment of Gram Negative BSI","status":"COMPLETED","sponsor":"The University of Queensland","startDate":"2019-10-28","conditions":"Bloodstream Infections","enrollment":513},{"nctId":"NCT03580044","phase":"PHASE3","title":"Efficacy, Safety, and Tolerability of ATM-AVI in the Treatment of Serious Infection Due to MBL-producing Gram-negative Bacteria","status":"TERMINATED","sponsor":"Pfizer","startDate":"2020-12-25","conditions":"Serious Bacterial Infection","enrollment":15},{"nctId":"NCT06084819","phase":"PHASE2","title":"Clinical Study of Venetoclax Combined With CACAG Regimen in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia","status":"UNKNOWN","sponsor":"Chinese PLA General Hospital","startDate":"2023-08-01","conditions":"Relapsed/Refractory Acute Myeloid Leukemia","enrollment":200},{"nctId":"NCT02101268","phase":"PHASE3","title":"Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF","status":"COMPLETED","sponsor":"Sierra Oncology LLC - a GSK company","startDate":"2014-06-19","conditions":"Primary Myelofibrosis (PMF), Post-polycythemia Vera (Post-PV), Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)","enrollment":156},{"nctId":"NCT03662126","phase":"PHASE2, PHASE3","title":"KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment","status":"UNKNOWN","sponsor":"Kartos Therapeutics, Inc.","startDate":"2019-01-15","conditions":"Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Post-Essential Thrombocythemia MF (Post-ET-MF)","enrollment":385},{"nctId":"NCT04366908","phase":"PHASE2","title":"Prevention and Treatment With Calcifediol of COVID-19 Induced Acute Respiratory Syndrome","status":"COMPLETED","sponsor":"Maimónides Biomedical Research Institute of Córdoba","startDate":"2020-05-07","conditions":"SARS-CoV 2, COVID19, SARS (Severe Acute Respiratory Syndrome)","enrollment":517},{"nctId":"NCT02913261","phase":"PHASE3","title":"Safety and Efficacy of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell Transplantation","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-03-10","conditions":"Corticosteroid Refractory Acute Graft vs Host Disease","enrollment":310},{"nctId":"NCT04876430","phase":"PHASE2, PHASE3","title":"Best Available Therapy With or Without Meropenem for Bloodstream Infections by Enterobacterales With High Level of Resistance to Carbapenems","status":"TERMINATED","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2021-05-04","conditions":"Carbapenem-Resistant Enterobacteriaceae Infection, Bloodstream Infection","enrollment":13},{"nctId":"NCT05421104","phase":"","title":"Ruxolitinib for Polycythemia Vera in Patients Resistant to or Intolerant of Hydroxyurea.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2020-11-27","conditions":"Polycythemia Vera (PV)","enrollment":1576},{"nctId":"NCT02055781","phase":"PHASE3","title":"Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia","status":"TERMINATED","sponsor":"CTI BioPharma","startDate":"2014-02","conditions":"Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis","enrollment":311},{"nctId":"NCT04954014","phase":"PHASE2","title":"Pilot Study of Single Dose Bevacizumab as Treatment for Acute Respiratory Distress Syndrome (ARDS) in COVID-19 Patients","status":"TERMINATED","sponsor":"Maimónides Biomedical Research Institute of Córdoba","startDate":"2020-09-01","conditions":"ARDS, Human, Coronavirus Infection","enrollment":21},{"nctId":"NCT02038036","phase":"PHASE3","title":"Ruxolitinib Efficacy and Safety in Patients With HU Resistant or Intolerant Polycythemia Vera vs Best Available Therapy.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-03-25","conditions":"Polycythemia Vera","enrollment":149},{"nctId":"NCT02962388","phase":"PHASE2, PHASE3","title":"The Ruxolitinib Versus Best Available Therapy Trial in Patients With High Risk ET in Second Line","status":"TERMINATED","sponsor":"French Innovative Leukemia Organisation","startDate":"2017-01-03","conditions":"Essential Thrombocythemia","enrollment":13},{"nctId":"NCT02218047","phase":"PHASE3","title":"AOP2014 vs. BAT in Patients With Polycythemia Vera Who Previously Participated in the PROUD-PV Study.","status":"COMPLETED","sponsor":"AOP Orphan Pharmaceuticals AG","startDate":"2014-11","conditions":"Polycythemia Vera","enrollment":170},{"nctId":"NCT02714595","phase":"PHASE3","title":"Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens","status":"COMPLETED","sponsor":"Shionogi","startDate":"2016-09-07","conditions":"Healthcare-associated Pneumonia (HCAP), Bloodstream Infections (BSI), Hospital Acquired Pneumonia (HAP)","enrollment":152},{"nctId":"NCT01773187","phase":"PHASE3","title":"Pacritinib Versus Best Available Therapy to Treat Myelofibrosis","status":"TERMINATED","sponsor":"CTI BioPharma","startDate":"2013-01","conditions":"Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis","enrollment":327},{"nctId":"NCT02396628","phase":"PHASE2","title":"Ruxolitinib In GvHD","status":"TERMINATED","sponsor":"Prof. Dr. Nikolas von Bubnoff","startDate":"2017-06-29","conditions":"Graft vs Host Disease","enrollment":22},{"nctId":"NCT00934544","phase":"PHASE3","title":"Controlled Myelofibrosis Study With Oral Janus-associated Kinase (JAK) Inhibitor Treatment-II: The COMFORT-II Trial","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-07-01","conditions":"Myelofibrosis","enrollment":219},{"nctId":"NCT01243944","phase":"PHASE3","title":"Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2010-10-27","conditions":"Polycythemia Vera","enrollment":222},{"nctId":"NCT02867891","phase":"","title":"Sorafenib In Relapse of FMS-like Tyrosine Kinase 3 (FLT3)-Internal Tandem Duplication (ITD) AML Trial","status":"COMPLETED","sponsor":"Robert Zeiser","startDate":"2001-03","conditions":"Acute Myeloid Leukemia","enrollment":396}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["BAT could include:","• Calcineurin inhibitor (cyclosporine or tacrolimus)","• Extracorporeal photopheresis (ECP)","• Mycophenolate mofetil (MMF)","• A mammalian target of rapamycin (mTOR) inhibitor (everolimus or sirolimus)"],"phase":"phase_3","status":"active","brandName":"Best Available Therapy (BAT)","genericName":"Best Available Therapy (BAT)","companyName":"BioVersys AG","companyId":"bioversys-ag","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}